118,95 €*
Versandkostenfrei per Post / DHL
Lieferzeit 4-7 Werktage
In recent years, drug discovery in the neurosciences has struggled to identify novel therapeutics for patients with varying indications, including epilepsy, chronic pain, and psychosis. Current treatment options for such patients are decades old and offer little relief with many side effects. One explanation for this lull in novel therapeutics is a lack of novel target identification for neurological disorders (and target identification requires exemplar preclinical data). To improve on the preclinical work that often relies on rodent modeling, the field has begun utilizing patient-derived induced pluripotent stem cells (iPSCs) to differentiate neurons in vitro for preclinical characterization of neurological disease and target identification.
In recent years, drug discovery in the neurosciences has struggled to identify novel therapeutics for patients with varying indications, including epilepsy, chronic pain, and psychosis. Current treatment options for such patients are decades old and offer little relief with many side effects. One explanation for this lull in novel therapeutics is a lack of novel target identification for neurological disorders (and target identification requires exemplar preclinical data). To improve on the preclinical work that often relies on rodent modeling, the field has begun utilizing patient-derived induced pluripotent stem cells (iPSCs) to differentiate neurons in vitro for preclinical characterization of neurological disease and target identification.
1. iPSC culture: best practices from sample procurement to reprogramming and differentiation
2. Phenotypic assay development with iPSC-derived neurons: technical
3. Derivation of cortical interneurons from human pluripotent stem cells to model neurodevelopmental disorders
4. Development of transcription factor-based strategies for neuronal differentiation from pluripotent stem cells
5. Differentiation of Purkinje cells from pluripotent stem cells for disease phenotyping in vitro
6. Brain organoids: models of cell type diversity, connectivity, and disease phenotypes Section II: The use of iPSC-derived neurons to study neurological disorders7. Human models as new tools for drug development and precision medicine
8. Use of cerebral organoids to model environmental and gene x environment interactions in the developing fetus and neurodegenerative disorders
9. iPSC-derived models of autism: Tools for patient phenotyping and assay-based drug discovery
10. Probing the electrophysiological properties of patient-derived neurons across neurodevelopmental disorders
11. Advantages and limitations of hiPSC-derived neurons for the study of neurodegeneration Section III: New technology, industry perspective, and transitioning to the clinic
12. Developing clinically translatable screens using iPSC-derived neural cells
13. Gene editing hPSCs for modeling neurological disorders
14. Cell therapy and biomanufacturing using hiPSC-derived neurons
15. Ethical considerations for the use of stem cell-derived therapies
| Genre: | Biologie |
|---|---|
| Rubrik: | Naturwissenschaften & Technik |
| Medium: | Taschenbuch |
| ISBN-13: | 9780128222775 |
| ISBN-10: | 0128222778 |
| Sprache: | Englisch |
| Herstellernummer: | C2019-0-04202-1 |
| Redaktion: | Buttermore, Elizabeth D. |
| Hersteller: |
Academic Press
Elsevier Science & Technology |
| Verantwortliche Person für die EU: | Zeitfracht Medien GmbH, Ferdinand-Jühlke-Str. 7, D-99095 Erfurt, produktsicherheit@zeitfracht.de |
| Abbildungen: | Approx. 100 illustrations (100 in full color) |
| Maße: | 234 x 190 x 235 mm |
| Von/Mit: | Elizabeth D. Buttermore |
| Erscheinungsdatum: | 15.09.2022 |
| Gewicht: | 0,75 kg |
1. iPSC culture: best practices from sample procurement to reprogramming and differentiation
2. Phenotypic assay development with iPSC-derived neurons: technical
3. Derivation of cortical interneurons from human pluripotent stem cells to model neurodevelopmental disorders
4. Development of transcription factor-based strategies for neuronal differentiation from pluripotent stem cells
5. Differentiation of Purkinje cells from pluripotent stem cells for disease phenotyping in vitro
6. Brain organoids: models of cell type diversity, connectivity, and disease phenotypes Section II: The use of iPSC-derived neurons to study neurological disorders7. Human models as new tools for drug development and precision medicine
8. Use of cerebral organoids to model environmental and gene x environment interactions in the developing fetus and neurodegenerative disorders
9. iPSC-derived models of autism: Tools for patient phenotyping and assay-based drug discovery
10. Probing the electrophysiological properties of patient-derived neurons across neurodevelopmental disorders
11. Advantages and limitations of hiPSC-derived neurons for the study of neurodegeneration Section III: New technology, industry perspective, and transitioning to the clinic
12. Developing clinically translatable screens using iPSC-derived neural cells
13. Gene editing hPSCs for modeling neurological disorders
14. Cell therapy and biomanufacturing using hiPSC-derived neurons
15. Ethical considerations for the use of stem cell-derived therapies
| Genre: | Biologie |
|---|---|
| Rubrik: | Naturwissenschaften & Technik |
| Medium: | Taschenbuch |
| ISBN-13: | 9780128222775 |
| ISBN-10: | 0128222778 |
| Sprache: | Englisch |
| Herstellernummer: | C2019-0-04202-1 |
| Redaktion: | Buttermore, Elizabeth D. |
| Hersteller: |
Academic Press
Elsevier Science & Technology |
| Verantwortliche Person für die EU: | Zeitfracht Medien GmbH, Ferdinand-Jühlke-Str. 7, D-99095 Erfurt, produktsicherheit@zeitfracht.de |
| Abbildungen: | Approx. 100 illustrations (100 in full color) |
| Maße: | 234 x 190 x 235 mm |
| Von/Mit: | Elizabeth D. Buttermore |
| Erscheinungsdatum: | 15.09.2022 |
| Gewicht: | 0,75 kg |
Ähnliche Produkte
Lieferzeit 1-2 Wochen
Lieferzeit 4-7 Werktage
Lieferzeit 1-2 Wochen
Lieferzeit 1-2 Wochen
Lieferzeit 2-3 Wochen